-+ 0.00%
-+ 0.00%
-+ 0.00%

Nicox says partner Ocumension submits NCX 470 NDA for China approval

PUBT·08/10/2026 05:30:21
Listen to the news
Nicox says partner Ocumension submits NCX 470 NDA for China approval
  • China partner Ocumension filed an NDA for NCX 470 with the NMPA to lower intraocular pressure in open-angle glaucoma.
  • Submission uses the same Phase 3 Mont Blanc and Denali data package as the recent U.S. FDA filing.
  • Nicox expects tiered royalties of 6% to 12% on Ocumension sales; Ocumension has paid EUR 18 million in license fees.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NicOx SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608100130PRIMZONEFULLFEED1001256527) on August 10, 2026, and is solely responsible for the information contained therein.